Variables | Nosocomial COVID-19 N = 39 (%)b | Matched control N = 70 (%)b | IRR (95%CI) | P value |
---|---|---|---|---|
Age, years, median (IQR) | 76 (15.5) | 73 (13) | 1.04 (1.00–1.07) | 0.024 |
Sex | ||||
Male | 23 (59.0%) | 49 (70.0%) | 0.62 (0.36–1.04) | 0.070 |
Underlying diseasec | ||||
Other Neurological Disorders | 4 (10.3%) | 2 (2.9%) | 2.04 (1.12–3.74) | 0.020 |
Fluid/Electrolyte Disorders | 14 (35.9%) | 10 (14.3%) | 3.16 (1.57–6.37) | 0.001 |
Elixhauser score (AHRQ) | ||||
Median (IQR) | 6 (19.5) | 7 (14) | 1.03 (-1.05) | 0.039 |
Mean (± SD) | 9.87 (11.72) | 8.38 (9.44) | ||
Laboratory findingsd | ||||
Abnormal WBC count | 5 (12.8%) | 13 (18.6%) | 0.63 (0.31–1.30) | 0.212 |
Abnormal Lymphocyte | 18 (46.1%) | 20 (28.6%) | 1.82 (1.12–2.94) | 0.016 |
Abnormal Creatinine | 18 (46.1%) | 24 (34.3%) | 1.49 (0.94–2.35) | 0.087 |
Abnormal Platelet | 5 (12.8%) | 7 (10.0%) | 1.00 (0.57–1.78) | 0.992 |
Abnormal Hemoglobin | 18 (46.1%) | 34 (48.6%) | 0.86 (0.56–1.32) | 0.492 |
Abnormal Neutrophil | 9 (23.1%) | 15 (21.4%) | 1.01 (0.58–1.74) | 0.984 |
Mobility-slightly limited or no limitations | 34 (87.2%) | 61 (87.1%) | 1.14 (0.54–2.44) | 0.726 |
Activity-walks occasionally or frequently | 27 (69.2%) | 60 (85.7%) | 0.38 (0.23–0.62) | 0.0001 |
Braden score, median (IQR) | 20 (18–21) | 20 (19–21) | 0.97 (0.90–1.05) | 0.482 |
Medications | ||||
Days on ACE inhibitors, mean (SD) | 0.82 (1.98) | 0.82 (1.85) | 0.99 (0.85–1.16) | 0.920 |
Days on angiotensin II inhibitors, mean (SD) | 1.05 (2.22) | 0.99 (2.20) | 1.03 (0.93–1.13) | 0.604 |
Days on angiotensin receptor blockers and neprilysin inhibitors, mean (SD) | 0.11 (0.71) | 0.06 (0.33) | 1.29 (0.78–2.14) | 0.321 |
Days on diuretic, mean (SD) | 3.03 (3.16) | 2.41 (2.83) | 1.09 (1.01–1.18) | 0.031 |
Days on immunosuppressive agents, mean (SD) | 0.52 (1.84) | 0.05 (0.51) | 1.33 (1.10–1.60) | 0.003 |